A generalized concept of power helped to choose optimal endpoints in clinical trials

被引:9
作者
Borm, George F.
van der Wilt, Gert J.
Kremer, Jan A. M.
Zielhuis, Gerhard A.
机构
[1] Radboud Univ Nijmegen Med Ctr, Dept Epidemiol & Biostat, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Dept Med Technol Assessment, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Obstet & Gynaecol, NL-6500 HB Nijmegen, Netherlands
关键词
power; sample size; statistical design; clinical trial; confidence interval; composite endpoints;
D O I
10.1016/j.jclinepi.2006.06.015
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: A clinical trial may have multiple objectives. Sometimes the results for several parameters may need to be significant or meet certain other criteria. In such cases, it is important to evaluate the probability that all these objectives will be met, rather than the probability that each will be met. The purpose of this article is to introduce a definition of power that is tailored to handle this situation and that is helpful for the design of such trials. Study Design and Setting: We introduce a generalized concept of power. It can handle complex situations, for example, in which there is a logical combination of partial objectives. These may be formulated not only in terms of statistical tests and of confidence intervals, but also in nonstatistical terms, such as "selecting the optimal by dose." Results: The power of a trial was calculated for various objectives and combinations of objectives. Conclusion: The generalized concept of power may lead to power calculations that closely match the objectives of the trial and contribute to choosing more efficient endpoints and designs. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:375 / 381
页数:7
相关论文
共 11 条
[1]   LOSS OF POWER FROM AN OPTIMISTIC ALTERNATIVE HYPOTHESIS [J].
BLUMENSON, LE .
STATISTICS IN MEDICINE, 1988, 7 (04) :457-466
[2]   An investigation of clinical studies suggests those with multiple objectives should have at least 90% power for each endpoint [J].
Borm, GF ;
Houben, RMGJ ;
Welsing, PMJ ;
Zielhuis, GA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2006, 59 (01) :1-6
[3]   ON THE USE OF A PILOT SAMPLE FOR SAMPLE-SIZE DETERMINATION [J].
BROWNE, RH .
STATISTICS IN MEDICINE, 1995, 14 (17) :1933-1940
[4]   A new method for choosing sample size for confidence interval-based inferences [J].
Jiroutek, MR ;
Muller, KE ;
Kupper, LL ;
Stewart, PW .
BIOMETRICS, 2003, 59 (03) :580-590
[5]   INCREASING SCIENTIFIC POWER WITH STATISTICAL POWER [J].
MULLER, KE ;
BENIGNUS, VA .
NEUROTOXICOLOGY AND TERATOLOGY, 1992, 14 (03) :211-219
[6]  
Pan ZY, 1999, STAT MED, V18, P1475, DOI 10.1002/(SICI)1097-0258(19990630)18:12<1475::AID-SIM144>3.3.CO
[7]  
2-S
[8]   Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues [J].
Sankoh, AJ ;
D'Agostino, RB ;
Huque, MF .
STATISTICS IN MEDICINE, 2003, 22 (20) :3133-3150
[9]   SAMPLE-SIZE REQUIREMENTS FOR INTERVAL ESTIMATION OF THE ODDS RATIO [J].
SATTEN, GA ;
KUPPER, LL .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1990, 131 (01) :177-184
[10]   A PREDICTIVE APPROACH TO SELECTING THE SIZE OF A CLINICAL-TRIAL, BASED ON SUBJECTIVE CLINICAL OPINION [J].
SPIEGELHALTER, DJ ;
FREEDMAN, LS .
STATISTICS IN MEDICINE, 1986, 5 (01) :1-13